{"entity":{"id":"hotspot-therapeutics","kind":"company","name":"HotSpot Therapeutics","aka":["HotSpot Therapeutics, Inc."],"tldr":"HotSpot Therapeutics is a Boston biotech that drugs the regulatory pockets of proteins rather than their active sites; its oral CBL-B inhibitor HST-1011 releases a brake on T cells.","summary":"HotSpot Therapeutics targets natural regulatory hotspots, allosteric sites that control protein function, using its Smart Allostery platform. Its first clinical candidate HST-1011 is an oral allosteric inhibitor of the E3 ubiquitin ligase CBL-B, an intracellular checkpoint that limits T-cell and natural killer cell activation. HST-1011 is in a phase 1/2 trial alone and with cemiplimab in advanced solid tumours; the company also develops an IRF5 inhibitor for autoimmune disease.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.hotspotthera.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["hst-1011"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Boston, Massachusetts","country":"US","companyType":"biotech","website":"https://www.hotspotthera.com/","founded":2017,"investors":[],"funding":[]},"route":"/companies/hotspot-therapeutics/","neighbours":{"drug":[{"id":"hst-1011","kind":"drug","name":"HST-1011","route":"/drugs/hst-1011/"}]}}